A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : SD / stable disease

[Related PubMed/MEDLINE]
Total Number of Papers: 2287
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   SD  (>> Co-occurring Abbreviation)
Long Form:   stable disease
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 18F-FDG PET/CT in Tuberculosis: Can Interim PET/CT Predict the Clinical Outcome of the Patients? ATT, CMR, DP, FRT, TB
2020 A comparison between drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis of six randomized controlled trials. CR, DC, DEB, OS, PR, TACE
2020 A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. CB, CR, CTCAE, EORTC, LC, MPR-OC, ORR, PR, PTV, RTOG, SBRT
2020 A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies. CBR, CRC, GIST, PR, RTKs
2020 A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors. MTD
2020 A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma. ACC, AEs, DLT, DLTs, MTD, PK, RECIST, SOAT1
2020 A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. DLT, IDO1, MTD, RP2D, SAEs
2020 A phase I study investigation of metabolism, and disposition of [14C]-anlotinib after an oral administration in patients with advanced refractory solid tumors. PD, PR, SAE, TRA
2020 A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. CHOAnome, DL, DLT, GBM, HGG, PR
10  2020 A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors. DCE-MRI, PR
11  2020 A Phase Ib Study to Evaluate the MEK Inhibitor Cobimetinib in Combination with the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors. AEs, MAPK
12  2020 A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. AE's, CI, DDLS, DSRCT, LMS, MLS, ORRs, PFS, PR, SS, STS
13  2020 A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy. CR, HMAs, MDS, PR
14  2020 A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma. GPNMB, MMAE, ORR, OS, PFS
15  2020 A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). CI, MPM, OS, PFS-6, PR
16  2020 A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. AEs, CR, ECOG, HN, mFUP, mOS, mPFS, PR, SGC
17  2020 A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. AGC, CERs, ICERs, OS, PFS
18  2020 A Randomized Phase 2 Study of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma. ACC, OS, PD-L1, PFS, RT, TGR
19  2020 A rare EGFR mutation L747P conferred therapeutic efficacy to both gefitinib and osimertinib: A case report. PFS, TKIs
20  2020 A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas. CR, LMS, PFS, PR, STS, UPS
21  2020 A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer. CI, CR, IVC, PR, TNBC
22  2020 A Retrospective Study of Rapid Symptom Response in Bleeding Gynecologic Malignancies With Short Course Palliative Radiation Therapy: Less is More. CR, PD, PR, RT
23  2020 A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer. AEs, DCR, NSCLC, ORR, PFS, PR
24  2020 Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib. CI, EGFR, NSCLC, OS, PFS, PR, TKI
25  2020 Adoptive transfer of zoledronate-expanded autologous Vgamma9Vdelta2 T-cells in patients with treatment-refractory non-small-cell lung cancer: a multicenter, open-label, single-arm, phase 2 study. DCR, NSCLC, ORR, OS, PFS
26  2020 An EGFR-Amplified Cervical Squamous Cell Carcinoma Patient with Pulmonary Metastasis Benefits from Afatinib: A Case Report. CN, PFS, PR
27  2020 Analysis of the clinical effect of osimertinib on 90 cases with advanced lung adenocarcinoma. DCR, EGFR-TKI, mOS, mPFS, NSCLC, ORR, PD, PR
28  2020 Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety. AEs, DCR, ORR, PD, PR, PROC, SAEs
29  2020 Assessment of the role of Ga-68 PSMA I&T PET/CT in response evaluation to docetaxel therapy in castration resistant prostate cancer patients. DT, IT, mCRPC, PCa, PD, PET/CT, PR, PSA, PSMA
30  2020 Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer. CD, NSCLC, OS, PD, PR
31  2020 Autologous dendritic cells pulsed with lysate from an allogeneic hepatic cancer cell line as a treatment for patients with advanced hepatocellular carcinoma: A pilot study. DCs, HCC, PD, PR, TACE
32  2020 Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. Ang-2, FGF, HCC, OR
33  2020 Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. BOR, HPV, IRC, ORR, PD-L1, PR, RECIST, SCCHN, TGF-beta, TRAEs
34  2020 Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy. PFS, SCLC, SUKSES, SUKSES-C
35  2020 Can Ipilimumab restore immune response in advanced NSCLC after progression on anti-PD-1/PD-L1 agents? DCR, ICPI, irAE, NSCLC, ORR, OS, PR
36  2020 Characteristics of Long-Term Survival in Patients With Myelodysplastic Syndrome Treated With 5-Azacyditine: Results From the Hellenic 5-Azacytidine Registry. HI, IPSS, MDS, WPSS
37  2020 Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma. CPIs, GVHD, HR, NRM, OS, PD, PFS, PTCy, SCT
38  2020 Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy. CR, DLT, HD-MTX, MTD, PCNSL, PD, PR, RT, TMZ
39  2020 Chronological Changes in Neutrophil/lymphocyte Ratio in Advanced Gastric Cancer Patients Treated with Nivolumab: a Report of Nine Cases. GC, NLR, PD, PR
40  2020 Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients. BM, cOC
41  2020 Clinical benefits of PD-1/PD-L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and meta-analysis. AE, CR, DCR, HCC, mAb, ORR, OS, PD, PFS, PR, SAE
42  2020 Clinical Effects of Neoadjuvant Chemotherapy in Treating Breast Cancer. CR, JBCS, MP, NAC, PD, PR, RECIST
43  2020 Clinical efficacy of intra-cavitary infusions of autologous dendritic cell/cytokine-induced killer cell products for the treatment of refractory malignant pleural effusions and ascites. CR, DC, PD, PR, QOL
44  2020 Clinical efficacy of Stereotactic Body Radiation Therapy (SBRT) for adrenal gland metastases: A multi-center retrospective study from China. AGM, CR, LC, OS, PD, PR, SBRT
45  2020 Clinical Experience of Bevacizumab for Radiation Necrosis in Patients with Brain Metastasis. BEV, BM, FLAIR, Gd, PR, RN
46  2020 Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy. CR, CRT, ESCC, OS, PD, PFS, PR
47  2020 Clinical Significance of the Initial and Best Responses after Chemoembolization in the Treatment of Intermediate-Stage Hepatocellular Carcinoma with Preserved Liver Function. CR, HCC, HR, OS, PR
48  2020 Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy. AEs, DCR, mOS, mPFS, ORR, OS, PD, PFR, PFS, PR
49  2020 Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience. CR, FDA, PD, PDGFRA, PFS, PR, STS
50  2020 Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis. AEs, CI, PFS, PR, TKIs
51  2020 Comparison of Image-Guided Iodine-125 Seed Interstitial Brachytherapy and Local Chemotherapy Perfusion in Treatment of Advanced Pancreatic Cancer. VAS
52  2020 Computational Modeling of Interstitial Fluid Pressure and Velocity in Non-small Cell Lung Cancer Brain Metastases Treated With Stereotactic Radiosurgery. CFM, DCE, IFP, LCBMs, OR, PD, sens, SRS
53  2020 Depth of Remission Following First-Line Treatment Is an Independent Prognostic Marker for Progression-Free Survival in Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. CR, H. pylori, MALT, PFS, PR
54  2020 Desmoid-type fibromatosis: Tumour response assessment using magnetic resonance imaging signal and size criteria. DF, MRI, PD, PR, RECIST
55  2020 Development of prediction models for the sensitivity of oral squamous cell carcinomas to preoperative S-1 administration. CR, FGs, OSCC, PD, PR
56  2020 Drug-eluting beads transarterial chemoembolization with CalliSpheres microspheres for treatment of unresectable intrahepatic cholangiocarcinoma. CR, CSM, DEB-TACE, ICC, OS, PD, PFS, PR
57  2020 DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies. BCLC, CR, DSM-TACE, HCC, mRECIST, PD, PR
58  2020 Durable Clinical Response of Advanced Lung Adenocarcinoma Harboring EGFR-19del/T790M/BRAFV600E Mutations After Treating with Osimertinib and Dabrafenib Plus Trametinib: A Case Report. TKIs
59  2020 Durvalumab activity in previously treated patients who stopped durvalumab without disease progression. PD-L1, PR
60  2020 Dynamic analysis of circulating tumor DNA to predict prognosis and monitor therapeutic response in metastatic relapsed cervical cancer. LACC, MRCC, MSG, OS, PFS, PR
61  2020 Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy. DCR, ORR, PFS, PR
62  2020 Effectiveness of bronchial arterial embolization using N-butyl-2-cyanoacrylate for local control of pulmonary hilar or mediastinal tumors that are refractory to chemotherapy. BAE, CR, NBCA, PD, PR
63  2020 Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study. AEs, DCR, EOC, ITT, OS, PFS, PP, PR
64  2020 Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib. AFP, DCR, LEN, mALBI, PFS, RAM, SOR, uHCC
65  2020 Efficacy and toxicity of sorafenib in patients with adenoid cystic carcinoma of the head and neck: a case series of five patients. ACC, AE, mTKI, PR, RR
66  2020 Efficacy of Moxifloxacin plus Treatment of Physician's Choice in Patients with Metastatic Breast Cancer. AEs, CI, MBC, PFS, TPC
67  2020 EGF+61 A>G polymorphism does not predict response to first-generation EGFR tyrosine kinase inhibitors in lung cancer patients. DP, EGF, PR, TKIs
68  2020 Evaluation of clinical efficacy of Chemotherapy for Rhabdomyosarcoma in children. CR, OS, PD, PR
69  2020 Evaluation of radioactive 125I seed implantation for the treatment of refractory malignant tumours based on a CT-guided 3D template-assisted technique: efficacy and safety. CR, CTV, PD, PR, PTV
70  2020 Evaluation of the Reliability of Interim PET/CT in the Hodgkin Lymphoma. CR, CT, DS, FDG, HL, PET, PR
71  2020 Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. CB, CI, CR, EEC, OR, PR
72  2020 Evolution of RAS Mutational Status in Liquid Biopsies During First-Line Chemotherapy for Metastatic Colorectal Cancer. ctDNA, ddPCR, mCRC, PR
73  2020 Extended Texture Analysis of Non-Enhanced Whole-Body MRI Image Data for Response Assessment in Multiple Myeloma Patients Undergoing Systemic Therapy. ADC, CR, DWI, FL, GLCM, GLRLM, IMC, IMWG, MM, NGTDM, NUN, PD, SAE, VOI
74  2020 Feasibility and prognostic benefit of induction chemoradiotherapy followed by surgery in patients with locally advanced non-small cell lung cancer. CR, ICRT, NSCLC, OS, PD, PR, RFS
75  2020 Fewer tumour draining sentinel nodes in patients with progressing muscle invasive bladder cancer, after neoadjuvant chemotherapy and radical cystectomy. CR, MIBC, NAC, PD, RC, SNd, SNs
76  2020 First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. AEs, CHP, NOD2, NY-ESO-1
77  2020 First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor. DRP, MTD, PRs
78  2020 Frameless Single Robotic Radiosurgery for Pulmonary Metastases in Colorectal Cancer Patients. CK, CR, CRC, DC, LC, mCRC, OS, PD, PFS, PR
79  2020 Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis. CR, DCR, DSA, FUDR, HAI, mOS, ORR, PR
80  2020 Identification of prognostic factors for gammadeltaT cell immunotherapy in patients with solid tumor. CI, FCM, HR, PD, PR
81  2020 Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors: A Systematic Review and Meta-Analysis. CR, irRC, PR, RECIST
82  2020 Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. CR, DCR, FGFR1-3, ORR, PR, UCB, UTUC
83  2020 Influence of pretreatment tumor growth rate on objective response of hepatocellular carcinoma treated with transarterial chemoembolization. CR, HCC, mRECIST, OR, PD, PR, TACE, TGR
84  2020 Intra-arterial Peptide Receptor Radionuclide Therapy using 90Y DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. AEs, CR, IA, IA, PD, PR, PRRT
85  2020 Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study. CBR, GIST, MR, PFS, SDH, WT
86  2020 Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. APAs, CR, PCs, PD, PR, TMZ
87  2020 Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting. CR, DCR, OS, PD, PFS, PR
88  2020 Long-term scintigraphic and clinical follow up in patients with differentiated thyroid cancer and iodine avid bone metastases. CR, DTC, IR, PD, PR, RAI-131
89  2020 Low dose continuous lenalidomide in heavily pretreated patients with relapsed or refractory classical Hodgkin lymphoma: a retrospective case series. ASCT, cHL, CR, LDC, PR, R/R
90  2020 Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms. AC, GR, HPLC, IEO, LC, MC, NECs, PR
91  2020 Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising? EHE, hEHE
92  2020 Mid-term response assessment in multiple myeloma using a texture analysis approach on dual energy-CT-derived bone marrow images - A proof of principle study. CR, DECT, GLCM, PR, VNC
93  2020 Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer. CR, OC, PFS, PR
94  2020 MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-alpha, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial. HCC, PR, TKIs
95  2020 Neuroendocrine Tumor Omic Gene Cluster Analysis Amplifies the Prognostic Accuracy of the NETest. PD
96  2020 Next-Generation Sequencing of Advanced GI Tumors Reveals Individual Treatment Options. MTBs, OS, PFS, PR
97  2020 NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. BTC, CR, OC, PDAC, PR
98  2020 Outcomes of retreatment with anti-PD-1 monotherapy after response to first course in patients with cutaneous melanoma. ---
99  2020 PD-L1+ lung cancer stem cells modify the metastatic lymph-node immunomicroenvironment in nsclc patients. CSCs, LNs, PD, PR
100  2020 PDGFD induces ibrutinib resistance of diffuse large B‑cell lymphoma through activation of EGFR. CR, DEGs, DLBCL, EGFR, GO, IHC, KEGG, PDGFD, PR